Ally Bridge invests in new medical tech

With offices in Hong Kong and New York, Ally Bridge has led more than $140 million in new financing rounds for three new medical technology companies in this Private Life Science Investments offering. Then new investments bring the total investments to more than $500 million over the last 18 months, officials said in a press statement. Ally Bridge manages over $2 billion in life science assets, both private and public, in the U.S., China, and Europe, from medtech to biopharmaceuticals. The firm is very active in publicly listed companies across the life science sector via its New York-based hedge fund Ally Bridge MedAlpha. The latest investments are Imperative Care, Venclose Medical and Mavrik Dental Systems. Each of the three companies is a commercial-stage innovator. Imperative is dedicated to improving the way stroke is treated by advancing medical technology. The California-based company received FDA approval for its first families of access and aspiration catheters. Venclose is developing solutions for the treatment of venous reflux disease, also known as chronic venous insufficiency. Based in Santa Clara, California, the company has been at the commercial stage in the U.S. and Europe since 2018. Based in Tel Aviv, Mavrik Dental offers technologies and products for in-office teeth whitening and gum care. This is Ally Bridge’s first investment in an Israel-based company. The global life science-focused investment firm was founded and led by Goldman Sachs and Och-Ziff Capital alum Frank Yu, CEO and CIO of Ally Bridge Group (ABG). “Medtech, as with biotech, remains a must-invest sector for ABG, where we focus on best-in-class technologies to disrupt current standards of care,” Yu said in a press statement. Over the last 18 months, the firm’s lead role in investments in a number of companies has total more than $500 million. Those underlying investments include early cancer detection company Grail, Pulmonx (interventional pulmonology), and Quantum Surgical (interventional oncology). “Our active investments that leverage powerful synergies across private and public markets, coupled with our M&A knowhow and cross-border value-add, position ABP uniquely as a leading investor in late-stage best-in-class life science technologies,” Yu added.

Ally Bridge invests in new medical tech

Continue Reading With a Free Trial

Pictet fundraising for thematic, tech PE fund of funds

Former Bessemer CIO joins Bridgewater

Welcome to Alternatives Watch

Buck hires former AndCo exec for manager research

Hybrid VC Firm rolls out second cannabis fund

Legendary trader Salem Abraham opens Fortress strategy to outside investors

HFR: HFs see first quarterly net inflow in two years

CSAM partners for sustainability platform

LLR closes latest fund with $1.8bn

Due diligence vet Randy Shain joins Hilton Global

PayPal’s crypto move wins investor support for digital currencies

Continue Reading With a Free Trial

Be an Alts Watcher

Subscribe to our mailing list and know first!

New York pension allocates over $400m in European alts

Siguler Guff taps MidOcean founding member to lead credit expansion

Related Articles

Get our daily news digest in your inbox

Get our daily news digest
in your inbox